Page 50 - Pharma Sector

AstraZeneca's Dapagliflozin tablets get DCGI nod for chronic kidney disease

AstraZeneca Pharma India on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for Dapagliflozin

Domestic drug market growth slows top 4.5% in January, some therapies drag

Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet

GlaxoSmithKline Pharmaceuticals reports net profit of Rs 157 cr in Q3

GlaxoSmithKline Pharmaceuticals on Friday said it has registered a consolidated net profit of Rs 156.51 crore for the third quarter ended December

GSK, CureVac to develop Covid-19 vaccines aimed at new variants

Drugmaker GlaxoSmithKline said Wednesday it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of COVID-19

Aurobindo Pharma, KAPL get nod for promotion of manufacturing bulk drugs

The government has given approval to drug firms includingAurobindo Pharma and Karnataka Antibiotics & Pharmaceuticals under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country. The setting up of plants under the scheme will lead to total committed investment of Rs 3,761 crore by the companies and employment generation for around 3,825 people,the Ministry of Chemicals and Fertilizers said in a statement. The applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production ofPenicillin G, and 7-ACA, with committed production capacity of15,000 MT and2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA isRs 813 crore, it added. The approval has also been given to Aurobindo Pharma (through Qule Pharma)

Four more Covid-19 vaccines are in pipeline, says health ministry

Four more COVID-19 vaccines are in the pipeline and their manufacturers may approach the drug controller for emergency use authorisation, the Health Ministry said on Tuesday.

Pfizer compiling data to answer DCGI queries on coronavirus vaccine

Drug major clarifies it could not present itself before the SEC because of short notice and time zone issues

Sun Pharma rises 3%, hits over 2-year high on steady earnings visibility

The board of directors of Sun Pharma are scheduled to meet on January 29, 2021 to consider and approve Q3 results

Domestic drug market bounces back in Dec, ends CY20 with 3.1% growth

Clocks 8.5% growth in December, up sharply from November's 1% due to revival in volume growth

Telecom, pharma on revival path as businesses limp back to pre-Covid levels

In the second part of the series, we are looking at the telecom, pharma, and automotive sectors

Pharma revenue, margins likely to remain healthy in next fiscal: ICRA

Revenue growth for IPM (Indian Pharmaceutical Market) is expected to be 7-9 per cent in FY2021 despite muted growth in Q1 FY2021

Indian pharma firms at high ransomware attack risk in 2021: Report

Targeted ransomware attacks on the healthcare and pharma sector are likely to surge in India in 2021: Report

FM stresses on more investments in biotech, pharma R&D ahead of budget

Says India has capacity to produce Covid vaccines for itself and other countries

Lupin rises on settling dispute with Gavis and Novel; gains 5% in four days

On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis and Novel transaction has been resolved amicably to the satisfaction of all parties.

Stuck in Sydney hotel, Astra CEO defended Covid vaccine and made mega deal

AstraZeneca announced Saturday it plans to buy rare-disease specialist Alexion Pharmaceuticals in a $39 billion deal

AstraZeneca to buy Alexion for $39 billion to expand in immunology

AstraZeneca is one of the frontrunners in the drugs industry's search for a Covid-19 vaccine

Steady sales, Covid-treatment portfolio could drive pharma rerating

Better US prospects, India recovery, boosting sector's outlook

Play markets for medium-term, diversify across asset classes: Amit Khurana

IT Services has been the biggest beneficiary of Covid-19 pandemic and is now a mainstream growth driver rather than a one-off line item

Domestic drug market shows resilience, posts strong growth in October

Maintains the growth momentum from September with a 9.6 per cent growth

Sun Pharma's Q2 net profit rises 70% on one-time tax credit

Revenues remain flat, sequential improvement in India and US revenues